Ultragenyx
RARE
Ultragenyx (RARE) news
Recent news
Ultragenyx shares rise 2.1% premarket after $203 million sale of priority review voucher for rare pediatric disease
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares rose 2.1% in premarket trading on October 14, 2026, following the announcement that the company had agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awarded by the U.S. Food and Drug Administration…
AInvest Wire · 16h agoUltragenyx to sell rare pediatric disease prv for $203M
AInvest Wire · 17h agoUltragenyx enters into agreement to sell rare pediatric disease priority review voucher for $203 million
AInvest Wire · 17h agoUltragenyx Pharmaceutical - Under deal with U.S. Department of Health Co to pay 20% of PRV sale proceeds to NIH - SEC filing
AInvest Wire · 7d agoUltragenyx to sell rare pediatric disease prv for $210M
AInvest Wire · 7d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.